Tom Frohlich Chinook Therapeutics, Inc. (KDNY) insider trading activity

KDNY Quotes by TradingView

Tom Frohlich is Chief Operating Officer of CHINOOK THERAPEUTICS, INC.. Currently has a direct ownership of 0 shares of KDNY, which is worth approximately $0. The most recent transaction as insider was on Aug 11, 2023, when has been sold 150,777 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
0% 12M change
Total Value Held $0

Tom Frohlich Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 11 2023
SELL
Sale (or disposition) back to the issuer
-
150,777 Reduced 100.0%
0 Common Stock
Feb 10 2023
SELL
Open market or private sale
$87,875 $23.75 p/Share
3,700 Reduced 2.4%
150,777 Common Stock
Feb 10 2023
BUY
Exercise of conversion of derivative security
-
6,803 Added 4.22%
154,477 Common Stock
Jan 31 2023
SELL
Open market or private sale
$112,688 $24.68 p/Share
4,566 Reduced 3.0%
147,674 Common Stock
Jan 31 2023
BUY
Exercise of conversion of derivative security
-
8,333 Added 5.19%
152,240 Common Stock
Dec 13 2022
SELL
Open market or private sale
$250,000 $25.0 p/Share
10,000 Reduced 6.5%
143,907 Common Stock
Dec 13 2022
BUY
Exercise of conversion of derivative security
$4,200 $0.42 p/Share
10,000 Added 6.1%
153,907 Common Stock
Nov 07 2022
SELL
Open market or private sale
$221,600 $22.16 p/Share
10,000 Reduced 6.5%
143,907 Common Stock
Nov 07 2022
BUY
Exercise of conversion of derivative security
$4,200 $0.42 p/Share
10,000 Added 6.1%
153,907 Common Stock
Oct 06 2022
SELL
Open market or private sale
$144,918 $19.69 p/Share
7,360 Reduced 4.87%
143,907 Common Stock
Oct 06 2022
BUY
Exercise of conversion of derivative security
-
13,582 Added 8.24%
151,267 Common Stock
Feb 11 2022
SELL
Open market or private sale
$47,584 $12.74 p/Share
3,735 Reduced 2.64%
137,685 Common Stock
Feb 10 2022
BUY
Exercise of conversion of derivative security
-
6,801 Added 4.59%
141,420 Common Stock
Nov 10 2021
SELL
Open market or private sale
$96,440 $15.48 p/Share
6,230 Reduced 4.42%
134,619 Common Stock
Nov 08 2021
SELL
Open market or private sale
$208,891 $15.17 p/Share
13,770 Reduced 8.91%
140,849 Common Stock
Nov 05 2021
SELL
Open market or private sale
$280,000 $14.0 p/Share
20,000 Reduced 11.45%
154,619 Common Stock
Nov 05 2021
BUY
Exercise of conversion of derivative security
$6,300 $0.42 p/Share
15,000 Added 7.91%
174,619 Common Stock
Oct 06 2021
SELL
Payment of exercise price or tax liability
$91,031 $12.37 p/Share
7,359 Reduced 4.41%
159,619 Common Stock
Oct 06 2021
BUY
Exercise of conversion of derivative security
-
13,580 Added 7.52%
166,978 Common Stock
Sep 24 2021
SELL
Open market or private sale
$260,000 $13.0 p/Share
20,000 Reduced 13.04%
133,398 Common Stock
Sep 24 2021
BUY
Exercise of conversion of derivative security
$8,400 $0.42 p/Share
20,000 Added 11.53%
153,398 Common Stock
Oct 05 2020
BUY
Grant, award, or other acquisition
-
153,398 Added 50.0%
153,398 Common Stock
TF

Tom Frohlich

Chief Operating Officer
Seattle, WA

Track Institutional and Insider Activities on KDNY

Follow CHINOOK THERAPEUTICS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KDNY shares.

Notify only if

Insider Trading

Get notified when an Chinook Therapeutics, Inc. insider buys or sells KDNY shares.

Notify only if

News

Receive news related to CHINOOK THERAPEUTICS, INC.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on KDNY